Compare PTRN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTRN | SYRE |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2015 |
| Metric | PTRN | SYRE |
|---|---|---|
| Price | $11.70 | $43.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $19.56 | ★ $55.57 |
| AVG Volume (30 Days) | ★ 1.0M | 672.7K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.65 | N/A |
| Revenue Next Year | $22.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.19 | $10.91 |
| 52 Week High | $20.10 | $45.76 |
| Indicator | PTRN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 65.40 |
| Support Level | $11.21 | $15.01 |
| Resistance Level | $15.09 | $45.76 |
| Average True Range (ATR) | 0.80 | 2.18 |
| MACD | 0.19 | -0.09 |
| Stochastic Oscillator | 66.39 | 80.37 |
Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.